Shots:
- Kaken Pharmaceutical has entered into a licensing agreement with KalVista Pharmaceuticals to obtain commercialization rights of sebetralstat in Japan
- As per the deal, KalVista will receive $11M upfront & $13M in regulatory (expected in early 2026) & commercial milestones, along with Japan NHI price-based royalties, with royalty rate as sales % approximately in the mid-20s
- Additionally, Japan’s MHLW has received NDA & granted ODD to sebetralstat (kallikrein inhibitor) for hereditary angioedema
Ref: Businesswire | Image: KalVista Pharmaceuticals & Kaken
Related News:- Alumis and Kaken Pharmaceutical Enter Collaboration & Licencing Deal for ESK-001’s Development & Commercialization in Japan
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
